Mereo BioPharma (MREO) Total Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has reported Total Liabilities for 10 consecutive years, with $6.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 28.29% year-over-year to $6.1 million in Q2 2026; TTM through Jun 2026 was $6.1 million, a 28.29% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, down 67.57% from the prior year.
• Total Liabilities was $6.1 million for Q2 2026 at Mereo BioPharma, down from $6.6 million in the prior quarter.
• Over five years, Total Liabilities peaked at $48.4 million in Q2 2022 and troughed at -$54.7 million in Q3 2023.
• A 5-year average of $8.0 million and a median of $10.8 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 129.63% in 2024 and plunged 67.57% in 2025, its largest moves.
• Over 5 years, Total Liabilities stood at $30.7 million in 2022, then slumped by 48.08% to $16.0 million in 2023, then slipped by 3.39% to $15.4 million in 2024, then sank by 67.57% to $5.0 million in 2025, then grew by 21.22% to $6.1 million in 2026.
• The last three Total Liabilities figures came in at $6.1 million (Q2 2026), $6.6 million (Q1 2026), and $5.0 million (Q4 2025), per Business Quant data.